Hence, it is crucial to investigate the mechanisms underlying acquired resistance to EGFR-TKIs and identify potential therapeutic targets that can restore tumor sensitivity to EGFR-TKIs to improve the efficacy of EGFR-TKI treatment and enhance patient outcomes. The gene discussed is EGFR; the disease is neoplasm.